Calypso Biotech B.V.

https://www.calypsobiotech.com

Calypso is a private biotechnology company focused on the research and development of novel biologics to address unmet medical need in autoimmune and inflammatory diseases. Calypso is developing a novel anti-IL-15 monoclonal antibody to treat a broad range of chronic autoimmune diseases by blocking Interleukin-15 (IL-15) and its wide-ranging functions at many levels of the immune response cascade. CALY-002, a highly potent monoclonal antibody, neutralizes all forms of IL-15 through a uniquely effective molecular mode of action to reduce inflammation and prevent tissue destruction. Calypso was founded by M Ventures, the corporate strategic venture arm of Merck, and is headquartered in Amsterdam, The Netherlands, with offices and laboratories in Geneva, Switzerland. Investors include M Ventures, Inkef Capital, Gilde Healthcare, Fountain Healthcare Partners and Johnson & Johnson Innovation – JJDC, Inc. *

	Start	2019-02-20 existent
	Group	Novartis (Group)
	Predecessor	Serono Pharmaceutical Research Institute
	Industry	CALY-001 (Calypso Biotech / EA Pharma)
	Industry 2	therapeutic antibody
	Person	Vicari, Alain (Calypso Biotech 201703 CEO)
	Person 2	Coulie, Bernard (Actogenix 201109 CEO + CMO)

	Region	Amsterdam
	Country	Netherlands
	Street	102 Gusta Mahlerlaan
	City	1082 MA Amsterdam
	Tel	+41-22-552-3307
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Calypso Biotech B.V.. (1/8/24). "Press Release: Calypso Enters into Agreement to Be Acquired by Novartis". Amsterdam.

		Record changed: 2024-02-12